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Advances in the prevention of paediatric pneumonia have led to 
a reduction in the burden of disease and have lowered the case 
fatality risk and mortality over the past two decades. Socioeconomic 
improvements, reduction in perinatal HIV transmission, effective 
antiretroviral therapy (ART) programmes, introduction of bacterial-
conjugate vaccines and improved immunisation coverage have 
changed the epidemiology and aetiology of childhood pneumonia 
in South Africa (SA). This section of the revised SA paediatric 
pneumonia guidelines presents current evidence aimed at prevention 
of childhood community-acquired pneumonia (CAP).
Prevention of childhood pneumonia
General preventive strategies 
General preventive strategies that reduce the incidence and severity 
of pneumonia are the following, and are summarised in Table 1.
Nutrition
Adequate nutrition and growth monitoring should be encouraged, 
as malnutrition predisposes children to pneumonia and severe 
illness. Breastfeeding has been shown to decrease the incidence of 
pneumonia in young children by up to 32%.[1] Shorter duration of 
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Background. More comprehensive immunisation regimens, strengthening of HIV prevention and management programmes and improved 
socioeconomic conditions have impacted on the epidemiology of paediatric community-acquired pneumonia (CAP) in South Africa (SA).
Objectives. To summarise effective preventive strategies to reduce the burden of childhood CAP.
Methods. An expert subgroup reviewed existing SA guidelines and new publications focusing on prevention. Published evidence on 
pneumonia prevention informed the revisions; in the absence of evidence, expert opinion was used. Evidence was graded using the British 
Thoracic Society (BTS) grading system. 
Recommendations. General measures for prevention include minimising exposure to tobacco smoke or air pollution, breastfeeding, 
optimising nutrition, optimising maternal health from pregnancy onwards, adequate antenatal care and improvement in socioeconomic 
and living conditions. Prevention of viral transmission, including SARS-CoV-2, can be achieved by hand hygiene, environmental 
decontamination, use of masks and isolation of infected people. Specific preventive measures include vaccines as contained in the Expanded 
Programme on Immunisation schedule, isoniazid prophylaxis for tuberculosis, co-trimoxazole prophylaxis for HIV-infected infants and 
children who are immunosuppressed, and timely diagnosis of HIV, as well as antiretroviral therapy (ART) initiation. HIV-infected children 
treated with ART from early infancy, and HIV-exposed children, have similar immunogenicity and immune responses to most childhood 
vaccines as HIV-unexposed infants.
Validation. These recommendations are based on available published evidence supplemented by the consensus opinion of SA paediatric 
experts, and are consistent with those in published international guidelines. 
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breastfeeding is associated with pneumonia mortality, particularly 
among infants <5 months of age.[2] Mortality among infants who are 
not breastfed compared with exclusively breastfed infants through 
5 months of age is ~15-fold higher (relative risk (RR) 14.97; 
95% confi dence interval (CI) 0.67 - 332.74).[2] Breastfeeding should 
be encouraged for the first 6 months of a child’s life, irrespective of 
maternal HIV or ART use,[3] and may be considered for the first 
2 years in children living with HIV (CLWH).[4] 
Table 1. Summary: Measures to prevent pneumonia in children
General preventive strategies Summary
Nutrition Malnourished children are at increased risk for severe pneumonia  
and mortality
Breastfeeding is protective 
Micronutrient supplementation
Vitamin A Vitamin A should be dosed according to the Road to Health card schedule
100 000 IU stat at 6 months; 200 000 IU stat at 12 months; 200 000 IU stat 
at 18 months 
From 24 months onwards, 200 000 IU every 6 months from 2 to 5 years of age
Vitamin D Vitamin D-deficient children are at increased risk for CAP, supplement with 
vitamin D 400 IU daily 
Zinc Zinc 10 mg (for infants) and 20 mg (for older children) daily significantly reduces 
the risk of pneumonia
Reduction in passive smoking and indoor fuel exposure Environmental exposure to cigarette smoke or indoor air pollution is strongly 
correlated with impaired lung health in children
Infection prevention and control and physical distancing Careful attention to limiting transmission of respiratory pathogens reduces the 
burden of respiratory illness
Hand hygiene
Cough etiquette
Decontamination of environmental surfaces
Use of masks
Specific preventive strategies
Immunisation Administered at
BCG Birth
Pneumococcal conjugate vaccine 6 weeks, 14 weeks and 9 months
Hib conjugate vaccine and pertussis vaccine 6 weeks, 10 weeks, 14 weeks and 18 months as part of the hexavalent vaccine 
Influenza vaccine  Not routinely administered in the SA EPI, but should be considered annually           
for children ≥6 months of age at risk for severe influenza, including those 
with congenital cardiac disease, chronic lung disease, immunosuppression and 
neuromuscular disease
Measles-containing vaccine 6 months and 12 months
Combination ART Expeditious initiation of ART at the earliest opportunity must be implemented 
routinely for all CLWH to restore immunological function and prevent infectious 
complications of HIV; ideally, the diagnosis should be made at birth and ART 
initiated within the first week of life
Prophylaxis
Prevention of PCP Co-trimoxazole prophylaxis is crucial in the prevention of PCP and all-cause 
mortality in CLWH and those with immunosuppression from other causes; refer to 
the SA paediatric ART guidelines for details and Box 1
Prevention of tuberculosis INH is an under-utilised preventive strategy in SA children exposed to a household 
contact with tuberculosis – INH 10 mg/kg × 6 months is recommended
CLWH or other underlying immunosuppression with a positive tuberculin skin test, even 
in the absence of a contact, should be given INH × 6 months. This may also be considered 
for children newly diagnosed with HIV. The maximum daily dose of INH is 300 mg
Prevention of CMV Although CMV pneumonia is considered to be an important infection in HIV-
infected infants, no recommendation on chemoprophylaxis has been adopted
Prevention of RSV The cost of monoclonal antibody prophylaxis (palivizumab) against RSV is 
very high ‒ therefore, widespread use is not feasible at a programmatic level; 
ex-premature infants <6 months of age, and those with congenital cardiac disease 
or chronic lung disease <1 year of age during the course of the RSV season, benefit 
most from this preventive measure given monthly through the season
CAP = community-acquired pneumonia; BCG = bacillus Calmette-Guérin; Hib = Haemophilus influenzae type b; SA = South Africa; EPI = Expanded Programme on Immunisation; 
ART = antiretroviral therapy; CLWH = children living with HIV; PCP = Pneumocystis jirovecii pneumonia; IPT = isoniazid-preventive therapy; INH = isoniazid; CMV = cytomegalovirus; 
RSV = respiratory syncytial virus.
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Micronutrient supplementation
Specific micronutrients that may play a role in the prevention of 
pneumonia are discussed below:
Vitamin A. Vitamin A supplementation reduces severity of 
respiratory complications of measles.[5] However, a meta-analysis of 
the impact of vitamin A supplementation on all-cause pneumonia 
morbidity and mortality showed no consistent effect on pneumonia-
specific mortality.[6] Provision of vitamin A supplementation in 
children with vitamin A deficiency has been associated with improved 
outcomes. 
Vitamin D. While empiric therapy using vitamin D in 
hospitalised children with CAP is not beneficial, observational 
studies have identified an increased risk of pneumonia in children 
<5 years old with subclinical vitamin D deficiency (evidence level III).[7] 
A meta-analysis of the role of vitamin D supplementation in pneumonia 
prevention found a significant protective effect (evidence level Ia).[8] 
However, in a clinical trial conducted in Asian children <5 years 
of age, oral doses of vitamin D had no protective effect on the 
incidence of the first episode of pneumonia (evidence level Ib).[9] 
Vitamin E. There is very little evidence to support vitamin E 
supplementation for the prevention of pneumonia in children 
(evidence level IVa).[10,11]
Zinc. Daily prophylactic elemental zinc, 10 mg (infants) and 
20 mg (older children), may substantially reduce the incidence of 
pneumonia, particularly in malnourished children.[12] A pooled 
analysis of randomised controlled trials of zinc supplementation 
in well-nourished and malnourished children found that children 
who received zinc supplementation had a significant reduction in 
pneumonia incidence compared with those who received placebo 
(odds ratio (OR) 0.59; CI 0.41 - 0.83) (evidence level Ia).[13] 
Reduction in tobacco smoke or indoor fuel exposure
Active and passive exposure to tobacco should be strongly 
discouraged in women of child-bearing age, particularly among 
pregnant women,[14] and more generally in the household.[15] 
Exposure to fumes from indoor cooking fuels should be limited 
by opening windows and doors when cooking; the chimney should 
function well; the stove should be cleaned and maintained; and there 
should be safe child location practices while fires are burning in the 
house.[16] The practice of carrying children on caregivers’ backs while 
cooking is an independent risk factor for pneumonia morbidity and 
mortality.[17] Children should sleep in rooms separate from where 
food is cooked (evidence level Ib).
Infection prevention, control, use of masks and physical 
distancing
Hand hygiene and respiratory etiquette are crucial in limiting 
interpersonal transmission of respiratory pathogens.[18,19] Reinforce-
ment of hand hygiene decreases the prevalence of respiratory tract 
illness in adults by 14% (95% CI 11 - 17) in non-pandemic influenza 
seasons.[20] A systematic review and meta-analysis of the effect of 
hand hygiene in limiting illness in children suggested that in primary 
and secondary schools, hand hygiene may decrease the incidence of 
respiratory tract infections among learners (evidence level Ia).[21] Although 
young children are not generally able to adhere to respiratory 
etiquette practices,[22] older children, caregivers and health workers 
should adopt these practices to limit the transmission of respiratory 
pathogens.[18] 
Universal use of cloth face masks by children and adults in public 
is an effective public health intervention to reduce transmission of 
respiratory viruses, including SARS-CoV-2, in addition to other 
public health measures.[23] In health facilities, all healthcare workers 
should wear a surgical mask in addition to practising hand hygiene, 
physical distancing and environmental decontamination to prevent 
SARS-CoV-2 transmission.[23] 
Specific preventive strategies
Immunisation
Routine immunisations
All children should receive routine vaccines, including bacillus 
Calmette-Guérin (BCG), measles, diphtheria-pertussis-tetanus (DPT) 
toxoid, Haemophilus influenzae type b (Hib), polysaccharide-protein 
conjugate vaccine (HibCV) and pneumococcal polysaccharide-
protein conjugate vaccine (PCV) as per the SA immunisation 
schedule.[24] The nature and degree of immunosuppression in 
CLWH may impact on the efficacy and duration of vaccine-induced 
protection.[25-29] CLWH treated with ART from early infancy, and 
responding well to such therapy, demonstrate similar immunogenicity 
and anamnestic immune responses to most childhood vaccines 
compared with HIV-unexposed infants.[30,31] HIV-exposed uninfected 
(HEU) infants may have lower concentrations of transplacental 
acquired antibodies for some vaccine-preventable diseases,[32,33] which 
could increase their susceptibility to pneumonia during early infancy. 
The immune responses to all vaccines are, however, similar or more 
immunogenic for HEU than for HIV-unexposed infants,[30,31] and 
there is similar persistence of protective antibody concentrations and 
memory responses.[34] 
Specific vaccines
BCG vaccine. Mycobacterium tuberculosis may be a direct pathogen 
in pneumonia or may predispose to bacterial infection (including 
from pneumococcus).[35,36] A birth dose of BCG vaccine is effective 
in preventing disseminated tuberculosis in young children, but has 
variable effectiveness (average 50%; range 0 - 84% effectiveness) in 
prevention of pulmonary tuberculosis, with lower effectiveness in 
studies on children from tropical countries.[37,38] A birth dose has also 
been shown to have nonspecific benefits in improving overall child 
survival in some settings.[39] 
Pneumococcal vaccine. Multiple post-licensure effectiveness 
studies (using 10- and 13-valent PCV) in a diversity of settings have 
demonstrated a 17% (95% CI 11 - 22) and 31% (95% CI 26 - 35) 
reduction in hospitalisation rates for clinically and radiologically 
confirmed pneumonia, respectively.[40] In children aged 24 - 59 months 
a meta-analysis found a reduction of 9% (95% CI 5 - 14) and 24% 
(95% CI 12 - 33) in hospitalisation rates for clinically and radiologically 
confirmed pneumonia, respectively (evidence level Ia).[40]
In SA, PCV (currently 13-valent) is administered at 6 and 14 weeks 
of age, followed by a booster dose at 9 months of age (evidence 
level Ib). This schedule has been shown to be effective in reducing 
all-cause pneumonia hospitalisation by 33% and 39% in CLWH and 
HIV-uninfected children, respectively.[41]
The 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23) is 
recommended for children >2 years old, who are at risk of developing 
invasive pneumococcal disease, including those with sickle cell 
disease, chronic pulmonary disease and cardiovascular disease,[42,43] 
and is included in the SA Essential Drugs List for paediatrics for 
administration to such patients. It should be preceded by a single 
dose of PCV, given at least 1 month before (evidence level III).[44,45] 
The need for further booster doses of PCV in older CLWH 
remains to be determined, but the indirect effect of childhood 
PCV immunisation in reducing transmission and circulation of 
vaccine-serotype pneumococci could mitigate waning of immunity 
in CLWH and other high-risk groups that remain susceptible to 
developing severe pneumonia in later childhood.[46] The World 
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Health Organization (WHO) currently recommends that a booster 
dose of PCV may be considered in the second year of life in CLWH 
(evidence level II).[47]
Hib conjugate vaccine. Vaccination with HibCV, as part of a 
combination vaccine, is recommended as a 3-dose primary series, 
and includes a booster dose at 15 - 18 months of age in SA. HibCV is 
less effective in CLWH not on ART;[48] however, the immunogenicity 
of the vaccine and persistence of memory responses in the second 
year of life are similar in CLWH vaccinated when already initiated on 
ART at the time of immunisation.[49] 
Pertussis vaccine. Pertussis remains one of the most poorly 
controlled vaccine-preventable diseases globally and causes severe 
disease in young infants (especially in those <3 months of age) and 
incompletely immunised children (evidence level Ib).[50,51] 
Pertussis vaccine formulations include whole-cell containing (wP) 
and Bordetella pertussis protein-only component acellular vaccines (aP). 
Whole-cell pertussis vaccines, but not aP protein-containing vaccines, 
induce mucosal immunity and protect against B. pertussis mucosal 
infection and transmission.[52] Furthermore, the duration of protection of 
wP is 8 - 12 years compared with 4 - 5 years for aP vac cines.[53] Currently, 
only aP-containing combination vaccines are available in SA. 
Pertussis outbreaks have been temporally associated with 
transitioning from wP to aP formulations in many high-resource 
settings, attributed to the waning of immunity in the absence of 
repeat booster doses at school entry and beyond.[53] Children primed 
with aP-containing vaccines should receive booster doses of aP 
vaccines (dTaP) at school entry and possibly every 10 years thereafter 
(not yet part of the Expanded Programme on Immunisation (EPI)) 
(evidence level II).[54]
Prevention of pertussis in very young infants, who are at greatest 
risk of severe disease, is not achievable through infant immunisation, 
and transitioning from wP to aP could increase the burden of 
pertussis in this group.[53] Acellular pertussis vaccination of pregnant 
women is 90% effective in reducing pertussis in infants <3 months 
of age (evidence level Ia).[55]
Influenza vaccine. Only the sub-unit inactivated influenza vaccine 
is available in SA for annual administration. There are limited data 
on its efficacy in children, ranging from 33% to 73%, depending 
on vaccine preparation and influenza subtype targeted.[56] Current 
evidence suggests that influenza vaccination is safe in CLWH; however, 
a randomised controlled trial failed to demonstrate vaccine efficacy.[57] 
Nonetheless, there remains a recommendation that CLWH should be 
offered influenza vaccination before the start of winter, particularly if 
they have underlying chronic lung disease (evidence level III).
Children >6 months of age with underlying medical conditions 
are considered a high risk for complications of influenza, and are 
prioritised for annual vaccination. Such children comprise those 
with chronic pulmonary disease (including asthma), cardiac disease, 
chronic renal or hepatic diseases, diabetes mellitus, metabolic dis-
orders, sickle cell anaemia and other haemoglobinopathies, morbid 
obesity, immunosuppression, cerebral palsy or other neuromuscular 
conditions.[58] Family members and siblings of such patients should 
also be vaccinated.[58] Two doses of inactivated influenza vaccine, admin -
istered 1 month apart, are recommended for children 6 months - 9 years 
of age who have never been vaccinated; and a single dose if immunised 
in previous seasons.[58] 
Recent randomised controlled trials have demonstrated that 
influenza vaccination of pregnant women was 50% efficacious in 
reducing polymerase chain reaction (PCR)-confirmed influenza 
illness in their infants until 24 weeks of age. In SA and Mali, 
vaccination of pregnant women was more effective in preventing 
influenza illness in infants during the first 3 months of life (vaccine 
efficacy ‒ 85%), with subsequent waning and a non-significant 
reduction between 3 and 6 months of age.[59] Maternal influenza 
vaccination also reduced all-cause clinically diagnosed severe 
pneumonia or pneumonia hospitalisation by 30% in infants during 
the first 6 months.[59,60] 
Influenza immunisation should ideally be administered prior to 
the onset of the influenza season (which typically occurs from May 
to September in SA),[61,62] but can also be given during the influenza 
season. Due to the potential of year-on-year genetic drift of seasonal 
influenza virus strains, current vaccine formulations are updated 
annually, and a repeat vaccination is required each year. 
Measles vaccine. Measles remains a public health concern, and 
failure to achieve and sustain high immunisation coverage rates 
(>95%) against this highly contagious virus results in ongoing 
outbreaks in a diversity of settings, including SA.[63,64] Recent changes 
in the epidemiology of measles include a greater susceptibility of 
disease in very young infants (as early as 4 months of age).[64] This 
is due to lower antibody concentrations in pregnant women who 
have acquired immunity through vaccination, rather than through 
wild-type virus exposure, as well as possible waning of immunity in 
women living with HIV.[65,66]
The WHO recommends that children receive 2 doses of the 
measles vaccine, the first at 9 months of age and a booster dose at 
15 - 18 months of age.[67] However, for infants born to women living 
with HIV, and in settings with a high risk of measles in young infants, 
an additional dose is recommended at 6 months of age.[67] In SA, a 
2-dose measles vaccination schedule is recommended, administered at 
6 and 12 months of age. This induces seroprotective titres in ~55% of 
infants following the first dose of vaccine, and in >98% in HIV-exposed 
and HIV-unexposed children after the second dose of vaccine.[68] 
Combination antiretroviral therapy
The use of ART to reconstitute immunity is very effective for 
decreasing the incidence of pneumonia and opportunistic infections 
in CLWH. Combination ART should be initiated on diagnosis of 
HIV in all children, irrespective of clinical or immunological staging. 
Screening for HIV infection in newborns of HIV-infected women 
by means of PCR testing at birth and repeated PCR testing during 
the infant and breastfeeding period is standard of care in SA, with 
initiation of ART as soon as possible after confirmation of HIV 
infection, and continued lifelong thereafter.
Prophylaxis
Prevention of Pneumocystis jirovecii pneumonia. Updated recommen -
dations for the management of CLWH were published in 2019 (South 
African ART guidelines) (Box 1).[69]
Although the WHO recommends Pneumocystis jirovecii pneumonia 
(PCP) prophylaxis for HEU infants from 4 to 6 weeks of age until HIV 
infection has been excluded after complete cessation of breastfeeding, 
two southern African randomised controlled trials have shown that 
co-trimoxazole confers no survival advantage over placebo in this 
subset of children; therefore, this is not recommended in SA.[70,71] 
Prevention of tuberculosis. All children <5 years of age exposed 
to a household tuberculosis contact or other close tuberculosis 
contact should be given isoniazid preventive therapy (IPT) (10 mg/kg; 
maxi mum dose 300 mg) daily for 6 months once tuberculosis disease 
has been excluded. CLWH exposed to a household contact should be 
given prophylaxis for 6 months, irrespective of their age. A 6-month 
course of IPT should also be given to tuberculin skin test (TST)-
positive CLWH, even in the absence of a known household contact.[72] 
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There are conflicting data on the use of primary IPT in CLWH in 
the absence of a tuberculosis contact.[73,74] Newly HIV-diagnosed and 
clinically symptomatic CLWH may benefit from a 6-month course of 
IPT, irrespective of TST results.
Short-course preventive therapy using rifampicin and isoniazid 
must not be used in the context of tuberculosis prevention in HIV-
exposed neonates born to mothers with active tuberculosis, as the 
rifampicin component interferes with the prevention of mother-to-
child transmission (PMTCT) regimens.[75]
Current WHO guidelines encourage use of preventive therapy with 
multidrug-resistant tuberculosis (MDR-TB) based on individualised 
risk assessment for children exposed to source cases. In children 
exposed to a source case with ofloxacin-susceptible M. tuberculosis, a 
6-month course of ofloxacin, ethambutol and high-dose isoniazid has 
been found to be well tolerated.[76] 
Prevention of cytomegalovirus disease in HIV-infected children. 
There is no evidence to support a specific intervention in the 
prevention of cytomegalovirus (CMV) disease in CLWH.[77]
Prevention of respiratory syncytial virus. Although the humanised 
monoclonal-specific antibody for the prevention of respiratory syncytial 
virus (RSV) infections (palivizumab) is available, it is very expensive. 
Children most likely to benefit are those at risk of severe RSV infection, 
i.e. babies born prematurely who are <6 months of chronological age 
at the onset of the RSV season, or children with chronic lung disease 
or congenital cardiac disease who are <1 year of age at the onset of the 
RSV season.[78] A meta-analysis on the effectiveness of palivizumab 
against RSV hospitalisation reported 71% (95% CI 46 - 84) effectiveness 
in infants born at <35 weeks’ gestatio nal age, and ~45% in those with 
chronic lung disease and congenital heart disease (evidence level Ia).[79] 
Palivizumab should be given monthly for the duration of the RSV season 
(from February to July) in most of SA.[80,81]
Other strategies for prevention of severe RSV disease in infants, 
including antenatal vaccination of expectant mothers and long-acting 
monoclonal antibody preparations, are currently under investigation. 
Conclusions
Improvements in the EPI, through inclusion of protein-polysaccharide 
conjugate vaccines targeting Hib and pneumococcus, and expansion 
of the ART programme to prevent paediatric HIV infection and treat 
CLWH, have reduced the burden of CAP in SA children. However, 
the socioeconomic determinants of health still place the majority 
of children in SA at risk of becoming ill with pneumonia, and 
concerted efforts are needed for intersectoral collaboration to bring 
about sustained reductions in the pneumonia burden of SA children. 
Pneumonia-specific preventive strategies are highly effective and 
require ongoing implementation and monitoring.
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